Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Daiichi Sankyo
AstraZeneca
Teva
Chubb
Colorcon
Chinese Patent Office
Fuji
Novartis
Mallinckrodt

Generated: October 20, 2017

DrugPatentWatch Database Preview

Olaparib - Generic Drug Details

« Back to Dashboard

What are the generic sources for olaparib and what is the scope of olaparib freedom to operate?

Olaparib
is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in two NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Olaparib has two hundred and sixty-three patent family members in forty-seven countries and twelve supplementary protection certificates in eleven countries.

There is one drug master file entry for olaparib. One supplier is listed for this compound.

Summary for Generic Name: olaparib

US Patents:8
Tradenames:1
Applicants:1
NDAs:2
Drug Master File Entries: see list1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list89
Clinical Trials: see list139
Patent Applications: see list325
Drug Prices:see low prices
DailyMed Link:olaparib at DailyMed

Pharmacology for Ingredient: olaparib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms
LYNPARZA
olaparib
TABLET;ORAL208558-002Aug 17, 2017RXYesYes► Subscribe► Subscribe ► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
TABLET;ORAL208558-001Aug 17, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
TABLET;ORAL208558-001Aug 17, 2017RXYesNo► Subscribe► SubscribeYY ► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
CAPSULE;ORAL206162-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
TABLET;ORAL208558-001Aug 17, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
TABLET;ORAL208558-001Aug 17, 2017RXYesNo► Subscribe► SubscribeYY ► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
CAPSULE;ORAL206162-001Dec 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
CAPSULE;ORAL206162-001Dec 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
CAPSULE;ORAL206162-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
TABLET;ORAL208558-002Aug 17, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: olaparib

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,662,818Phthalazinone derivatives► Subscribe
7,351,701Therapeutic compounds► Subscribe
7,692,006Phthalazinone derivatives► Subscribe
7,750,006Phthalazinone derivatives► Subscribe
9,169,235Phthalazinone derivatives► Subscribe
9,566,276Phthalazinone derivatives► Subscribe
8,071,579DNA damage repair inhibitors for the treatment of cancer► Subscribe
7,531,530Therapeutic compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: olaparib

Country Document Number Estimated Expiration
Canada2547077► Subscribe
Hong Kong1056880► Subscribe
Canada2875147► Subscribe
Colombia5650256► Subscribe
SloveniaEP2346495► Subscribe
BrazilPI0412909► Subscribe
Austria528296► Subscribe
Australia2009300866► Subscribe
Norway20091882► Subscribe
Russian Federation2010149166► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: OLAPARIB

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
15/016Ireland► SubscribePRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
/2015Austria► SubscribePRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216
500012Hungary► SubscribePRODUCT NAME: OLAPARIB
00726Netherlands► SubscribePRODUCT NAME: OLAPARIB, EN ZOUTEN EN; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
680Luxembourg► SubscribePRODUCT NAME: OLAPARIB AINSI QUE DES SELS ET DES SOLVATES DE CELUI-CI. FIRST REGISTRATION: 20141218
3 50005-2015Slovakia► SubscribePRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: EU/1/14/959 20141218
2015016Lithuania► SubscribePRODUCT NAME: OLAPARIBUM; REGISTRATION NO/DATE: EU/1/14/959 20141216
0150012 00136Estonia► SubscribePRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014
90019-4Sweden► SubscribePRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218
2015 00012Denmark► SubscribePRODUCT NAME: OLAPARIB, OG SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/14/959/001 20141216
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
QuintilesIMS
Chubb
Julphar
AstraZeneca
Mallinckrodt
Argus Health
US Army
Citi
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot